ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.15% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2013-12-31 was 2.66%, a 66.25% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2013-09-30 was 1.96%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2013-03-31 was 0.90%, a 0.00% change year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2012-12-31 was 1.60%, a 77.78% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.96%, a 197.74% increase from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.33%, a 18.40% decline from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.63%, a 37.79% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.62%, a 18.13% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 4.15% 10-Q · filed 2026-08-11 | ||||
| 2025-12-31 | 3.74% S-1 · filed 2026-09-11 | ||||
| 2023-12-31 | 4.36% S-1 · filed 2026-09-11 | ||||
| 2022-12-31 | 3.96% 10-K · filed 2023-03-31 | ||||
| 2021-12-31 | 1.33% 10-K · filed 2023-03-31 | 133.00% 10-K · filed 2022-03-30 | |||
| 2020-12-31 | 1.63% 10-K · filed 2022-03-30 | ||||
| 2019-12-31 | 2.62% 10-K · filed 2022-03-30 | ||||
| 2018-12-31 | 3.20% 10-K · filed 2021-03-12 | ||||
| 2017-12-31 | 2.50% 10-K · filed 2020-03-06 | ||||
| 2016-12-31 | 2.35% 10-K · filed 2019-03-14 | ||||
| 2016-06-30 | 2.15% 10-K · filed 2016-10-13 | ||||
| 2015-12-31 | 1.87% 10-K · filed 2018-03-16 | ||||
| 2015-06-30 | 2.32% 10-K · filed 2016-10-13 | ||||
| 2014-06-30 | 2.70% 10-K · filed 2016-10-13 | ||||
| 2014-03-31 | 2.66% 10-Q · filed 2014-05-09 | ||||
| 2013-12-31 | 2.66% 10-Q · filed 2014-02-14 | 2.66% 10-Q · filed 2014-02-14 | |||
| 2013-09-30 | 1.96% 10-Q · filed 2013-11-14 | ||||
| 2013-06-30 | 0.80% 10-K · filed 2015-10-09 | ||||
| 2013-03-31 | 0.90% 10-Q · filed 2013-05-15 | 1.60% 10-Q · filed 2013-05-15 | |||
| 2012-12-31 | 1.60% 10-Q · filed 2013-02-14 | 1.60% 10-Q · filed 2013-02-14 | |||
| 2012-06-30 | 1.90% 10-K · filed 2014-09-29 | ||||
| 2012-03-31 | 0.90% 10-Q · filed 2013-05-15 | 1.90% 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | 0.90% 10-Q · filed 2013-02-14 | 1.90% 10-Q · filed 2013-02-14 | |||
| 2011-09-30 | 1.90% 10-Q · filed 2012-11-14 | ||||
| 2011-06-30 | 2.90% 10-K · filed 2013-09-11 | ||||
| 2010-06-30 | 3.90% 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |